Advisors Asset Management Inc. Acquires 1,191 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Advisors Asset Management Inc. boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 180.2% during the third quarter, HoldingsChannel reports. The fund owned 1,852 shares of the medical instruments supplier’s stock after purchasing an additional 1,191 shares during the quarter. Advisors Asset Management Inc.’s holdings in LeMaitre Vascular were worth $172,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. NBC Securities Inc. raised its position in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the period. West Oak Capital LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter valued at approximately $58,000. USA Financial Formulas acquired a new position in shares of LeMaitre Vascular in the 3rd quarter worth approximately $60,000. Finally, nVerses Capital LLC boosted its stake in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Performance

LMAT stock opened at $106.99 on Friday. The stock’s 50 day simple moving average is $95.52 and its 200 day simple moving average is $87.89. The company has a market cap of $2.41 billion, a P/E ratio of 58.46, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89. LeMaitre Vascular, Inc. has a fifty-two week low of $51.70 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the prior year, the firm earned $0.33 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 15.6% on a year-over-year basis. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analysts Set New Price Targets

LMAT has been the subject of a number of analyst reports. JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital initiated coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.